Targeting emerging viruses with phage display-driven engineered antibodies: Bridging molecular design and clinical...

Area of Science:

• Biotechnology
• Immunology
• Virology

Background:

• The COVID-19 pandemic underscored the need for rapid antibody development against mutable viruses like SARS-CoV-2.
• Phage display (PD) technology offers a powerful platform for accelerating antibody discovery and engineering.

Purpose of the Study:

• To provide a comprehensive review of PD-derived therapeutic antibodies for infectious diseases.
• To focus on SARS-CoV-2 targeting antibodies in clinical and preclinical development.
• To highlight the application of PD in generating potent neutralizing and multispecific antibody formats.

Main Methods:

• Review of existing literature and case studies on PD applications.
• Analysis of PD-derived antibodies for SARS-CoV-2, including approved agents and clinical candidates.
• Examination of PD's role in generating multispecific antibodies and elucidating viral mechanisms.

Main Results:

• PD enables rapid, high-throughput identification and optimization of neutralizing antibodies without animal immunization.
• PD-derived antibodies offer enhanced breadth, affinity, and serve as tools for studying viral pathogenesis.
• Successful application of PD in generating potent neutralizing and multispecific antibody formats for SARS-CoV-2.

Conclusions:

• Phage display is a versatile, rapid-response platform for developing therapeutic antibodies against infectious diseases.
• Strategic leveraging of PD's strengths is crucial for accelerating translational outcomes in future outbreaks.
• Advances in PD workflows position it as a robust framework for addressing current and future infectious disease challenges.